C. Fisher

J. Helterbrand, C. Fisher, A. Simpson, 2006, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: Time for a reevaluation

Charles J. Fisher, Michael A. Matthay, S. Opal, 2000, Critical care medicine.

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.

S. Opal, S. Lowry, C. Fisher, 1996, The New England journal of medicine.

The efficacy and safety of recombinant human activated protein C for the treatment of patients with severe sepsis (vol 28, pg 48, 2000)

Gary Garber, Jay Steingrub, Pierre-François Laterre, 2001 .

Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature.

D. Cook, D. Heyland, C. Fisher, 1995, Critical care medicine.

Measures, markers, and mediators: Toward a staging system for clinical sepsis. A Report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25–26, 2000

D. Cook, J. Marshall, G. Rubenfeld, 2003, Critical care medicine.

Blood ammonia levels in hepatic cirrhosis: their control by the oral administration of neomycin.

C. Fisher, W. Faloon, 1957, The New England journal of medicine.

Episodic stupor following portacaval shunt; observations on etiology and therapy.

C. Fisher, W. Faloon, 1956, The New England journal of medicine.

Clinical experience with the use of neomycin in hepatic coma.

C. Fisher, W. Faloon, 1959, A.M.A. archives of internal medicine.

Blood ammonia in chronic pulmonary emphysema.

C. Fisher, A. Renzetti, R. Dutton, 1959, The New England journal of medicine.

Arteriovenous shunting in palmar erythema; the effect upon blood ammonia determinations.

C. Fisher, R. Eich, W. Faloon, 1958, The Journal of laboratory and clinical medicine.

Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial

R. F. Johnston, Robert W. Taylor, Steven C. Johnson, 1994 .

Hypothermia in the sepsis syndrome and clinical outcome

T. Clemmer, R. Bone, C. Fisher, 1992, Critical care medicine.

Efficacy and safety of recombinant human activated protein C for severe sepsis

J. Helterbrand, J. Barkun, G. Bernard, 2003 .

Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

S. Opal, J. Vincent, S. Lowry, 1997, Critical care medicine.

Accidental mediastinal entry via left internal jugular vein cannylation

C. Fisher, T. Albertson, Z. Vera, 2004, Intensive Care Medicine.

Protein C levels as a prognostic indicator of outcome in sepsis and related diseases

C. Fisher, S. Yan, S. Yan, 2000, Critical care medicine.

A prolonged severe intoxication after ingestion of phenytoin and phenobarbital.

C. Fisher, R. Baselt, T. Albertson, 1981, The Western journal of medicine.

Prolonged bromide intoxication resulting from a gastric bezoar.

C. Fisher, T. J. Iberti, B. Patterson, 1984, Archives of internal medicine.

FORTY-THREE DIALYSES IN A COMMUNITY HOSPITAL.

C. Fisher, W. Loeser, G. Boulis, 1965, JAMA.

Cardiorespiratory failure in toxic shock syndrome: Effect of dobutamine

C. Fisher, T. Albertson, B. Horowitz, 1985, Critical care medicine.

Influence of an anti‐tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis

J. Vincent, J. Zimmerman, C. Fisher, 1993, Critical care medicine.

Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group.

W. Knaus, E. Draper, D. Wagner, 1996, Critical care medicine.

The Treatment of Sepsis with Interleukin-1 Receptor Antagonist

C. Fisher, S. Opal, J. Pribble, 1994 .

The HA-1A monoclonal antibody for gram-negative sepsis.

C. Sprung, C. Mecher, H. Feldman, 1991, The New England journal of medicine.

Influence of alterations in foregoing life-sustaining treatment practices on a clinical sepsis trial. The HA-1A Sepsis Study Group.

C. Sprung, R. Pizov, C. Fisher, 1997, Critical care medicine.

Immunotherapy of sepsis syndrome: a comparison of the available treatments.

C. Fisher, G. Bellingan, 1991, Klinische Wochenschrift.

Needle biopsy of the liver: comparison of initial clinical and histological diagnoses, with a note on postbiopsy mortality in patients with metastatic neoplasm.

C. Fisher, W. Faloon, 1958, The American journal of medicine.

Effect of lobar acid injury on pulmonary perfusion and gas exchange in dogs.

C. Fisher, L. Wood, 1980, Journal of applied physiology: respiratory, environmental and exercise physiology.

Early goal-directed therapy in the treatment of severe sepsis and septic shock

J. Helterbrand, P. Singer, T. Evans, 2002 .

Detrimental effects of high-dose methylprednisolone sodium succinate on serum concentrations of hepatic and renal function indicators in severe sepsis and septic shock. The Methylprednisolone Severe Sepsis Study Group.

T. Clemmer, R. Bone, C. Fisher, 1994, Critical care medicine.

An evaluation of the hemodynamic effects of HA‐1A human monoclonal antibody

C. Sprung, J. Zimmerman, C. Fisher, 1994, Critical care medicine.

Effect of nitroprusside on pulmonary hypertension and lung fluid balance after E. Coli endotoxin

C. Fisher, R. Demling, G. Foulke, 1982, Critical Care Medicine.

Protein nutrition and the biochemical composition of the uterus.

C. Fisher, J. Leathem, R. Oslapas, 1968, Fertility and sterility.

EFFECT OF FAT-POOR DIET UPON NEOMYCIN INDUCED MALABSORPTION.

C. Fisher, W. Faloon, M. Rubert, 1964, Gastroenterology.

The Treatment of Sepsis

S. Opal, M. Haller, J. Briegel, 1910, Intensive Care Medicine.

The Rapid Acute Physiology Score.

C J Fisher, K J Rhee, K. J. Rhee, 1987, The American journal of emergency medicine.

Fibrous dysplasia of the axis. A case report.

C. Fisher, A. Stirrat, I. Fyfe, 1989, Spine.

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group.

S. Opal, R. Greenman, C. Fisher, 1994, JAMA.

The Clnical Spectrum of Toxic Shock Syndrome

C. Fisher, B. Horowitz, S. Nolan, 2005 .

Higher urine desmosine levels are associated with mortality in patients with acute lung injury.

Arthur S Slutsky, W. Sibbald, T. Clemmer, 2006, American journal of physiology. Lung cellular and molecular physiology.